Emrosi™ (minocycline hydrochloride extended-release capsules) is now available for the treatment of inflammatory lesions (papules and pustules) of rosacea ...

Bhatia emphasized that patient weight and rosacea severity based on inflammatory lesion count do not affect treatment efficacy of sub-antibiotic dosing. “It’s really important not to have that ...

“The results of these placebo-controlled randomized clinical trials demonstrate that minocycline is efficacious and provides significantly superior outcomes in rosacea compared with placebo and ...

A study found that DFD-29 was more effective than both doxycycline and placebo, with a favorable risk-benefit profile for ...

Rosacea Therapeutics Market Analysis of Rosacea Therapeutics Market Covering 30+ Countries Including Analysis of US, Canada, UK, Germany, F ...

“As the lowest-dose oral minocycline on the market, Emrosi delivers significantly superior clinical outcomes for rosacea compared to placebo and Oracea® while maintaining a comparable safety profil ...

In the Minocycline Versus Oracea® in Rosacea-1 (MVOR-1) and Minocycline Versus Oracea in Rosacea-2 (MVOR-2) trials, subjects were randomized to receive DFD-29, Oracea, or placebo. The co-primary ...

Journey Medical (DERM) announced the launch of and the first prescriptions filled for Emrosi(TM) (40 mg Minocycline Hydrochloride Modified-Release Capsules, 10 mg immediate release and 30 mg extended ...

In the Minocycline Versus Oracea® in Rosacea-1 (MVOR-1) and Minocycline Versus Oracea in Rosacea-2 (MVOR-2) trials, subjects were randomized to receive DFD-29, Oracea, or placebo. The co-primary ...

Recent advancements in rosacea treatment, such as topical minocycline and topical oxymetolazone, focus on reducing inflammation and addressing the underlying immune system reactions that ...